On April 30, 2024, the landscape of the cannabis industry experienced a monumental shift when the US Drug Enforcement Administration announced its decision to reclassify cannabis from a schedule I to schedule III substance under the Controlled Substances act. This move, coming after an 18 month review initiated by the Biden administration, is seen as a significant step towards acknowledging the therapeutic potential of cannabis and easing federal restrictions that have long hampered the industry.

Read the full article.

About the authors:
Mason E. Freeman
Aulica Lin Monroe
Morgan E. Persinger
Al Windham